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A CpG Mutational Hotspot in a ONECUT Binding Site
Accounts for the Prevalent Variant of Hemophilia B Leyden
Alister P.W. Funnell,1 Michael D. Wilson,2,7 Benoit Ballester,3,8 Ka Sin Mak,1 Jon Burdach,1
Natisha Magan,4 Richard C.M. Pearson,1 Frederic P. Lemaigre,5 Kathryn M. Stowell,4
Duncan T. Odom,2,6 Paul Flicek,3,6 and Merlin Crossley1,*
Hemophilia B, or the ‘‘royal disease,’’ arises from mutations in coagulation factor IX (F9). Mutations within the F9 promoter are associ-
ated with a remarkable hemophilia B subtype, termed hemophilia B Leyden, in which symptoms ameliorate after puberty. Mutations
at the 5/6 site (nucleotides 5 and 6 relative to the transcription start site, designated þ1) account for the majority of Leyden cases
and have been postulated to disrupt the binding of a transcriptional activator, the identity of which has remained elusive for more than
20 years. Here, we show that ONECUT transcription factors (ONECUT1 and ONECUT2) bind to the 5/6 site. The various hemophilia
B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees, which correlate well with their
associated clinical severities. In addition, expression of F9 is crucially dependent on ONECUT factors in vivo, and as such, mice deficient
in ONECUT1, ONECUT2, or both exhibit depleted levels of F9. Taken together, our findings establish ONECUT transcription factors as
the missing hemophilia B Leyden regulators that operate through the 5/6 site.Hemophilia B (MIM 306900) is an X-linked recessive
blood-clotting disorder that affects approximately 1 in
every 30,000 males.1 It is also infamously known as the
‘‘royal disease’’ because it afflicted European royal families
descended from Queen Victoria.2 It is caused by mutations
that affect the normal expression or function of coagula-
tion factor IX (F9 [MIM 300746]). Interestingly, mutations
within the F9 proximal promoter are associated with
a specific subtype, known as hemophilia B Leyden (MIM
306900), which was first reported in the Netherlands.3
Sufferers of hemophilia B Leyden express low levels of F9
up until puberty, at which point F9 levels rise and clinical
symptoms improve; this phenomenon is associated
with increasing androgen receptor and growth-factor
activity.4–8
To date, more than 80 families affected by hemophilia
B Leyden have been analyzed worldwide and 21 distinct
point mutations have been detected in the F9 promoter
(Figure 1).12,13 The mutations fall into three clusters: one
at nucleotide 20 relative to the transcription start site
(TSS, designated þ1), one at around nucleotide þ10, and
one at nucleotides –5 and –6 (5/6 site). The mutations
at 20 prevent binding of the transcriptional activator
HNF4a (hepatocyte nuclear factor 4a, encoded by HNF4A
[MIM 600281]), and the þ10 mutations disrupt a C/EBPa
site (CCAAT/enhancer-binding protein a, encoded by
CEBPA [MIM 116897]).6,14,15 However, around half of all
known Leyden mutations lie in the third cluster, and their
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consensus site for the transcription factor ONECUT1
(encoded by ONECUT1 [MIM 604164]), also known as
hepatocyte nuclear factor 6 (HNF6).10 Importantly,
ONECUT1 is abundant in the liver, the tissue in which
F9 is produced.16 We thus sought to determine whether
ONECUT1 and the related protein ONECUT2 (encoded
by ONECUT2 [MIM 604894])17,18 constitute the missing
Leyden regulators that operate through the 5/6 site.
To test whether ONECUT1 and ONECUT2 could recog-
nize the 5/6 site in the human F9 promoter, we first
cloned the DNA-binding domains of ONECUT1 (residues
280–465) and ONECUT2 (residues 321–504) and fused
them each individually to the C terminus of glutathione
S-transferase (GST) contained in the vector pGEX-6P.
Recombinant GST-fusion proteins were subsequently
expressed in bacteria and were purified with glutathione
beads as described previously.19 The DNA-binding activi-
ties of the resulting extracts were assessed in electropho-
retic mobility shift assays (EMSAs) with a double-stranded,
radiolabeled DNA probe encompassing the 5/6 region
of the human F9 promoter (50-AACTAATCGACCTTA
CCA-30). As shown in Figure 2A, strong binding was
observed for both ONECUT1 and ONECUT2. We also
tested probes containing the hemophilia-B-Leyden-associ-
ated mutations (6G>C, 6G>A, 5A>T, and 5A>G).
The 6G>C mutation most significantly impaired bind-
ing, 6G>A had the mildest effects, and the two 5 muta-
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Figure 1. The Proximal Promoter of Human F9
The major transcription start site (TSS) is indicated by an arrow and designated þ1. Point mutations associated with hemophilia
B Leyden are indicated above the sequence. The transcription factors known to bind this region are shown, and the consensus sequences
that they recognize are aligned below the sequence. DNA-binding consensus sequences were determined from the ChIP-Seq data
reported here (ArrayExpress accession number E-MTAB-890) and previously (ArrayExpress E-TABM-722)9 with the default settings of
MEME and the following parameters: -revcomp -maxw 20 -minw 6 -nmotifs 5. We selected the top 500 peaks ordered by input-corrected
read depth and used the 25 base pairs centered on the identified summit of the peak as our input for the motif-discovery analysis. The
position weight matrices are consistent with previously determined DNA-binding consensuses for these transcription factors.9–11 The
following protein abbreviations are used: HNF4a, hepatocyte nuclear factor 4 alpha; C/EBPa, CCAAT/enhancer-binding protein alpha;
and OC1/2, ONECUT1/2.the clinical severity of the various mutations: the 6G>C
mutation produces the most severe hemophilia, 6G>A
produces the mildest form, and the 5 mutations are of
intermediate severity.12,13,20
We next assayed full-length ONECUT1 and ONECUT2
expressed in COS cells by using pCMV6-XL5 expression
vectors (OriGene). COS cells were transfected and nuclear
extracts were obtained as described previously.21,22 No
significant retarded bands were observed in untransfected
cells, but strong binding was observed when ONECUT1
or ONECUT2 was overexpressed (Figure 2B). Again, all
four Leyden mutations reduced the binding observed.
ONECUT1- and ONECUT2-specific antibodies (sc-13050
X and sc-51177 X, respectively; Santa Cruz Biotechnology)
supershifted the retarded species, confirming the identities
of these protein-DNA complexes (Figure S1, available
online). The reduced binding of full-length ONECUT1
and ONECUT2 to the 5/6 Leyden mutants was
further confirmed by competition assays using radiola-
beled wild-type probe and 03, 103, 1003, and 1,0003
excesses of cold competitor probe (Figure 2F and Figures
S2 and S3).
Next, we assessed nuclear extracts from murine liver
(3 months of age). As shown in Figure 2C, we detected
a single, distinct protein-DNA complex by using the
wild-type probe. The addition of antibodies individually
specific to ONECUT1 and ONECUT2 demonstrated
that the retarded species contained both proteins but
predominantly had ONECUT1 (Figure 2C). We then
examined the binding of the complex to the Leyden
mutant probes. Again, the intensity of this band was
reduced when probes carrying the mutations were usedThe Ame(Figure 2D), and the degree of impairment correlated
with the clinical severity of the mutation. Together,
these data suggest that ONECUT1 and ONECUT2 (but
particularly ONECUT1) constitute the majority of DNA-
binding activity at the 5/6 site in the liver and that
the Leyden mutations disrupt binding of these endoge-
nous factors.
Extensive mapping of the F9 locus has illustrated the
prevalence of CpG dinucleotides as hotspots for mutation
in hemophilia B cases.23 In this regard, it is interesting
that although both residues 6 and 7 are within a CpG
dinucleotide, no C>T transition has been reported at 7
(Figure 1). In contrast, mutations at6 have been reported
at least 34 times and account for nearly half of all Leyden
individuals.12,13 Importantly, the high incidence of this
mutation is not simply due to a founder effect, because
different haplotypes have been shown to be associated
with the 6 mutation.24 Our assertion that ONECUT
proteins operate in vivo predicts that the7C>Tmutation
might occur naturally but that it would not have a func-
tional effect on F9 expression, perhaps because it would
not disrupt ONECUT binding.
We used EMSAs with ONECUT1 and ONECUT2 GST-
fusion proteins to test whether the anticipated muta-
tion at 7 would impair binding of ONECUT factors
(Figure 2E). We observed both ONECUT1 and ONECUT2
binding—slightly less than that observed with the wild-
type sequence but significantly more than observed
with the 6G>A mutation (compare with Figure 2A).
Furthermore, competitor assays revealed that full-length
ONECUT1 and ONECUT2 bind to probes containing
the 7C>T mutation with considerably higher affinityrican Journal of Human Genetics 92, 460–467, March 7, 2013 461
Figure 2. ONECUT Proteins Recognize the 5/6 Region of the Human F9 Promoter, and Binding Is Disrupted by LeydenMutations
(A–F) EMSAs using wild-type (WT) and mutant probes spanning the 5/6 region.
(A) ONECUT1 and ONECUT2 GST-fusion proteins purified from bacteria. Coomassie staining is shown on the right to indicate the
level and purity of the recombinant proteins used.
(B) Nuclear extracts from COS cells expressing full-length ONECUT1 and ONECUT2.
(C) Murine liver nuclear extracts with antibodies against ONECUT1 and ONECUT2.
(D) Murine liver nuclear extracts with WT and mutant probes. Nuclear extracts from COS cells transfected with ONECUT1 and
ONECUT2 were included as positive controls.
(E) ONECUT1 and ONECUT2 GST-fusion proteins purified from bacteria. Equivalent levels of protein were added as in (A).
(F) A competition assay using radiolabeled WT probe (1.6 ng per lane) and cold competitor probes (0 ng, 16 ng, 160 ng, and 1.6 mg,
that is, 03, 103, 1003, and 1,0003 excesses, respectively) compares the ability of the different mutants to compete for binding by
ONECUT1. Twomicroliters of nuclear extracts from COS cells expressing ONECUT1 was used per lane. Murine liver tissue was obtained
under ethics approval number 09/128A (Animal Care and Ethics Committee, University of New South Wales). The following protein
abbreviations are used: OC1, ONECUT1; and OC2, ONECUT2.than to any of the Leyden-associated mutations (Figure 2F
and Figure S2). Thus, we conclude that 7C>T mutations
would produce a minimal phenotype, and we propose
that this is the reason that they have never been clinically
encountered. Taken together, the investigations of the base
substitutions at the 5, 6, and 7 sites concur well with
the position weight matrix determined for ONECUT1
(Figure 1). The 5 and 6 sites, which are robustly
conserved in the model, considerably disrupt binding
when mutated, whereas the 7 site, which is more flexible
and less conserved, is able to tolerate substitution.
To confirm in vivo binding at the F9 promoter, we
performed ONECUT1 chromatin immunoprecipitation
(ChIP) on murine liver tissue as described previously.25,26
Primers used are outlined in Table S1, and quantitative
real-time PCR (qRT-PCR) runs were performed with Power
SYBR Green PCR Master Mix and the 7500 Fast Real-Time
PCR System (Applied Biosystems).22 Data analysis was462 The American Journal of Human Genetics 92, 460–467, March 7conducted with 7500 Software v.2.0.4 (Applied Bio-
systems). As shown in Figure 3A, occupancy was detected
immediately upstream of F9, but not at more distal loca-
tions (1.0 kb downstream and 1.5 kb upstream). Moreover,
ONECUT1 was not detected at the proximal promoters
of other liver-enriched genes, namely, coagulation factor
VII (F7 [MIM 613878]) or factor X (F10 [MIM 613872]).
We also carried out ONECUT1 ChIP sequencing (ChIP-
seq) on human liver tissue. Human liver material (from
two males of unknown age) was obtained from the
Liver Tissue Distribution Program (National Institute of
Diabetes and Digestive and Kidney Diseases contract
N01-DK-9-2310) at the University of Pittsburgh and
Addenbrooke’s Hospital, Cambridge under human tissue
license 08/H0308/117. Immunoprecipitated material was
end repaired, A tailed, ligated to single- or paired-end
sequencing adapters, amplified by 18 cycles of PCR,
and size selected (200–300 bp); this was followed by, 2013
Figure 3. ONECUT1 Binds the F9 Promoter In Vivo along with HNF4a and C/EBPa
(A) ONECUT1 ChIP using mouse liver tissue. Primer sets are specific to the TSS of F9 and to 1.0 kb downstream and 1.5 kb upstream.
Negative-control primers specific to the promoter regions of F7 and F10 were included. Enrichment was normalized to input, and
the lowest values for immunoglobulin G (IgG) and anti-ONECUT1 were set to 1.0. Error bars represent the SEM, and n ¼ 3 for
each data point. *p < 0.05 (two-tailed t test) compared to the anti-ONECUT1 enrichment at each of the F9 distal regions and the
F7 and F10 promoters.
(B–C) Human-liver-tissue ChIP-Seq tracks for ONECUT1, C/EBPa, and HNF4a across the F9 locus (B) and around the TSS (C).
(C) The HNF4a, ONECUT1, and C/EBPa binding sites at nucleotides 20, 5/6, and þ10, respectively, are denoted by colored boxes.
Murine liver tissue was obtained under ethics approval number 09/128A (Animal Care and Ethics Committee, University of New South
Wales). ChIP sequencing reads and input samples were alignedwithMAQwith default parameters to NCBI Genome browser build 36. All
sequence, genome-annotation, and comparative-genomics data were taken from Ensembl release 52. After alignment, binding events
were discovered with a dynamic programming algorithm (SWEMBL) with the parameter ‘‘-R 0.005 -i –S’’ as previously described.27
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Figure 4. ONECUT Proteins Are Functionally Required for F9 Expression
(A) A Luciferase reporter assay in HepG2 cells. Wild-type (WT) andmutant F9 promoter fragments were tested in the presence or absence
of ONECUT1. Triplicate, independent DNA preparations for the promoter constructs were used. Firefly levels were normalized with the
use of Renilla, and the value for the WT promoter in the absence of ONECUT1 was set to 1.0. *p < 0.02 for 5/6 mutant promoters
relative to the WT promoter, and **p < 0.05 for the WT and 7C>T promoters in the presence compared to the absence of ONECUT1
(two-tailed t tests). n ¼ 3 for each data point or genotype, and error bars represent the SEM.
(B and C) qRT-PCR analysis of the expression of F9 and other liver genes in embryonic day (E) 17.5 livers from WT and Onecut1/ and
Onecut2/ single-knockout (KO) mice (B) and qRT-PCR analysis of E15.5 livers from WT and Onecut1//Onecut2/ double-knockout
(DKO) mice (C). Expression was normalized to 18S rRNA for all genes, and WT levels were set to 1.0. Murine liver tissue was obtained
under ethics approval number 09/128A (Animal Care and Ethics Committee, University of New South Wales). *p < 0.002, **p < 0.02
(two-tailed t tests). n ¼ 3 for each data point or genotype, and error bars represent the SEM. The following protein abbreviations are
used: OC1, ONECUT1; and OC2, ONECUT2.
(D) Agarose gel showing ethidium-bromide-stained amplicons from (C).single-end sequencing on an Illumina Genome Analyzer II
according to the manufacturer’s instructions. Data have
been deposited in ArrayExpress and assigned the accession
number E-MTAB-890. Analysis of the human F9 locus
found a strong ONECUT1 peak over the 5/6 site
(Figures 3B and 3C). Similarly, human ChIP-seq data for
HNF4a and C/EBPa, which we had previously reported
(ArrayExpress E-TABM-722),9,25 revealed at the F9 pro-
moter a high level of occupancy corresponding to the sites
that are mutated in hemophilia B Leyden and to which
these factors have been reported to bind in vitro (Figures
3B and 3C). Thus, ONECUT1, HNF4a, and C/EBPa all
bind to the F9 promoter in vivo and together encompass
all 21 reported point mutations associated with hemo-
philia B Leyden (Figure 1).
We next tested the functional effect of ONECUT1 and
ONECUT2 on the F9 promoter by means of reporter assays
in HepG2 cells as described previously.22 We used a frag-
ment that encompassed a minimal region (189 to þ21)464 The American Journal of Human Genetics 92, 460–467, March 7of the human F9 promoter and that had previously been
shown to recapitulate key aspects of the Leyden phenotype
in transfection studies and transgenic mice.15,28 This
region was cloned into the firefly luciferase vector
pGL4.10[luc2] (Promega). Cells in 6-well plates were trans-
fected (FuGENE6, Roche Diagnostics) with 1 mg triplicate
DNA preparations of pGL4.10[luc2] (wild-type or Leyden
mutants of the –189 to þ21 region) together with 100 ng
of the Renilla luciferase vector pGL4.74[hRluc/TK] (Prom-
ega) as a transfection control. Expression of ONECUT1
and ONECUT2 was achieved with 1 mg pCMV6-XL5
(ONECUT1 or ONECUT2) (OriGene). We found that
both ONECUT1 and ONECUT2 could potently transacti-
vate the wild-type promoter but had less activity on the
Leyden mutant promoters (Figure 4A and Figure S4). We
also found that compared to the wild-type promoter, the
7C>T promoter did not appreciably reduce transacti-
vation (Figure 4A), consistent with the view that such a
mutation does not functionally impair ONECUT binding., 2013
Lastly, it should also be noted that C/EBPa and HNF4a are
expressed in HepG2 cells.29,30 This raises the possibility
that in these cells, the ONECUT proteins might synergisti-
cally activate the F9 promoter constructs in combination
with either or both of these endogenous factors.
The results demonstrate that ONECUT proteins can bind
to and activate the F9 promoter in experimental systems.
To determine whether F9 expression is dependent on
ONECUT proteins in vivo, we analyzed tissue from
Onecut/ mice.31,32 Because ONECUT1-deficient mice
typically die shortly after birth, we assessed F9 expression
in fetal liver. Total RNA was extracted from fetal livers
and used as a template for cDNA synthesis by standard
methods. qRT-PCR was performed as described above and
with primer sequences shown in Table S2. We observed
clear reductions in F9 expression in both Onecut1/ and
Onecut2/ single knockouts (6-fold and 3-fold, respec-
tively) at day 17.5 of gestation (Figure 4B). Given that
both ONECUT1 and ONECUT2 can bind the 5/6 site
and could thus potentially compensate in each other’s
absence, we next examined tissues from Onecut1/
Onecut2/ double-knockout animals. These animals die
in utero, so we analyzed the liver at embryonic day 15.5,
when F9 was already expressed and the embryos were still
viable. We observed a dramatic reduction (>100-fold) in F9
levels in Onecut1/ Onecut2/ double-knockout samples
(Figures 4C and 4D). Importantly, we found near-normal
expression of a panel of other liver-specific genes,
including F7, F10, and coagulation factor XI (F11 [MIM
264900]), and of the other transcription factors
(HNF4a6,14 and C/EBPa12) known to drive F9, indicating
that the deficit in F9 is specific and not due to a general
failure in liver development at this embryonic stage
(Figures 4C and 4D).
In conclusion, we have established that the missing
regulators in hemophilia B Leyden are the ONECUT tran-
scription factors ONECUT1 and ONECUT2. These proteins
bind to the proximal promoter and drive expression of F9.
Their binding, and hence functional activity, is disrupted
by 5/6 base substitutions, which are found in more
than half of all individuals with hemophilia B Leyden.
We have shown here that the different Leyden mutations
at 5/6 disrupt ONECUT binding to varying degrees in
a manner that correlates well with their clinical severities.
It should be noted, however, that other factors might also
influence the severity of hemophilia in individual cases,
and we thus caution against solely using the mutations
to predict clinical outcome.
The comprehensive compilation of hemophilia
B mutations worldwide provides what might be the most
complete mapping of a human gene promoter.12,13
Detailed consensus sequences have now been determined
for HNF4a, ONECUT1, and C/EBPa9–11 (data presented
here), and the mutations associated with hemophilia
B Leyden fit remarkably well with predictions from these
consensus sequences (Figure 1). In the position weight
matrices for these transcription factors, the most robustlyThe Ameconserved bases are, by and large, those that are mutated
in cases of hemophilia.
These proteins are also relevant in terms of under-
standing the liver-restricted expression of F9. HNF4a,
ONECUT1, and C/EBPa are well known asmajor regulators
of hepatocyte gene expression,33 and this regulatory
module satisfyingly explains the liver-restricted expres-
sion pattern of F9. Their cognate DNA elements are very
tightly clustered within the F9 promoter, and the fact
that disruption of any single site severely disrupts
promoter activity suggests that these transcription factors
must cooperate to ensure proper F9 expression.
Taken together, these findings contribute to a thorough
characterization of the human F9 promoter and its
transacting factors and provide an illustrative example
of how disrupted local promoter architecture can result
in human disease.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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